LEXEO Therapeutics Closes $100 Million Series B Financing

Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors


Proceeds to support continued preclinical pipeline development in rare cardiovascular diseases and the genetics of Alzheimer’s disease; clinical development of the company’s lead programs toward meaningful data catalysts


NEW YORK – Sept. 9, 2021 (GLOBE NEWSWIRE) – LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic conditions, today announced that it closed a $100 million Series B financing, led by D1 Capital Partners and Eventide Asset Management, and joined by CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners, and existing investors Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners LP, Invus Capital, and Alexandria Venture Investments.



LEXEO TX Press Release_Series B_Final_9.2
.pdf
Download PDF • 166KB

563 views